New trends in the etiopathogenesis of diabetic peripheral neuropathy

Journal of Child Neurology

Volumn 16, Issue 6, 2001, Pages 389-394

  Verrotti, Alberto ^a   Giuva, T ^a   Chiarelli, F ^a   Morgese, G ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; SOMATOMEDIN;

ADOLESCENT; ADULT; AUTONOMIC NEUROPATHY; CELL TYPE; CONTROLLED STUDY; DIABETIC NEUROPATHY; ETIOLOGY; GLYCATION; HUMAN; HYPERGLYCEMIA; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; METABOLISM; MORBIDITY; MORTALITY; NEUROTROPISM; PATHOGENESIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW;

ADOLESCENT; ADULT; CHILD; DIABETES MELLITUS, TYPE 1; DIABETIC NEUROPATHIES; HUMANS; RISK FACTORS;

EID: 0034930149     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/088307380101600601     Document Type: Review

References (103)

1. Epidemiological correlates of diabetic neuropathy
2. Diabetic neuropathy in childhood
3. A standard test of heat-pain responses using CASE IV
4. Pathologic alterations in the diabetic neuropathies of humans: A review
5. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment on the development and progression of long-term complication in insulin-dependent diabetes mellitus
6. Diabetes Control and Complications Trial Research Group: Effect of intensive diabetes treatment on the development and progression of long-term complication in adolescents with insulin-dependent diabetes and Complications Trial
7. Elevated vibration perception threshold in young patients with type 1 diabetes in comparison to nondiabetic children and adolescents
8. Autonomic and peripheral nerve function in adolescents with and without diabetes
9. The use of biothensiometry to detect neuropathy in children and adolescents with IDDM
10. Subclinical nerve dysfunction in children and adolescents with IDDM
11. Diabetic neuropathy: A clinical and histological study on the significance of vascular affections
12. Diabetes Control and Complications Trial Research Group: The effect of intensive diabetes therapy on the development and progression of neuropathy
13. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: The EURODIAB IDDM Complications Study
14. Role of height and glycodylated haemoglobin in abnormal nerve conduction in pediatric patients with type 1 diabetes mellitus after 9 yr of disease
15. Progression of subclinical polyneuropathy in young patients with type 1 (insulin-dependent) diabetes: Associations with glycaemic control and microangiopathy (microvascular complications)
16. Has one diabetic complication been explained?
17. Albumin permeation of new vessels is increased in diabetic rats
18. Sorbinil prevents diabetes-induced increases in vascular permeability but does not alter collagen cross-linking
19. Islet transplants in diabetic Lewis rats prevent and reverse diabetes-induced increases in vascular permeability and prevent but do not reverse collagen solubility changes
20. Early arteriolar and capillary changes in streptozotocin-induced diabetic rats and intraperitoneal hyperglyceramic rats
21. Alterations in microvascular reactivity in experimental diabetes mellitus: Contribution of the endothelium
22. Increased susceptibility to ischemic damage in streptozotocin-diabetic nerve
23. Mild ischemia causes severe pathological changes in experimental diabetic nerve
24. Elevated plasma endothelin in patients with diabetes mellitus
25. Neurovascular [1251]-ET-1 binding sites on human peripheral nerve
26. Diabetes increases sciatic nerve susceptibility to endothelin-induced ischemia
27. Acute endoneurial ischemia induced by epineurial endothelin in the rat sciatic nerve
28. Autonomic neuropathy in diabetic children
29. Risk factors for diabetic somatic neuropathy
30. Nonenzymatic glycosylation and the pathogenesis of diabetic complications
31. Excessive nonenzymatic glycosylation of peripheral and central nervous system components in diabetic rats
32. Recognition and uptake of human diabetic peripheral nerve myelin by macrophages
33. Peripheral neuropathy in mouse hereditary diabetes mellitus
34. Posttranslation modifications of nerve cytoskeletal proteins in experimental diabetes
35. Glycation of rat sciatic nerve tubulin in experimental diabetes mellitus
36. Advanced glycated end-products in diabetic children and adolescents and its relation to metabolic control and microvascular complication
37. Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats
38. Effects of insulin and dietary myo-inositol on impaired peripheral motor nerve conduction velocity in acute streptozotocin diabetes
39. Action of sorbinil in diabetic peripheral nerve: Relationship of polyol (sorbitol) pathway to a myo-inositol mediated defect in sodium-potassium ATPase activity
40. Reversal by treatment with an aldose-reductase inhibitor, of impaired axonal transport and motor nerve conduction velocity in experimental diabetes mellitus
41. A sodium-pump defect in diabetic peripheral nerve corrected by sorbinil administration: Relationship to myo-inositol and nerve conduction slowing
42. Alfa, beta I, beta II, delta and epsilon protein kinase C isoforms and compound activity in the sciatic nerve of normal and diabetic rats
43. Glucose-induced alterations in nerve metabolism: Current perspective on the pathogenesis of diabetic neuropathy and future directions for research and therapy
44. Protein kinase C isozyme expression in sciatic nerves and spinal cords of experimentally diabetic rats
45. Over diabetic neuropathy: Repair of axo-glial dysjunction and axonal atrophy by aldose-reductase inhibition and its correlation to improvement in nerve conduction velocity
46. Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro
47. +-channel displacement is associated with nerve-conduction slowing in the chronically diabetic BB/W rat: Prevention by aldose-reductase inhibition
48. Sorbitol, phosphoinositides, and sodium-potassium ATPase in the pathogenesis of diabetic complications
49. Neuropathies encountered in the spontaneously diabetic BB wistar rat
50. Pharmacological manipulation of vascular endothelium function in non-diabetic and streptozotocin-diabetic rats: Effects of nerve conduction, hypoxic resistance and endoneurial capillarization
51. + ATPase activity in rabbit aorta by hyperglycaemia. Possible role of endothelium-derived nitric oxide
52. Nerve ischaemia in diabetic rats: Time-course of development, effect of insulin treatment plus comparison of streptozotocin and BB models
53. + ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat
54. Hyperglycemic pseudohypoxia and diabetic complications
55. Cp-45, 634: A novel aldose reductase inhibitor that inhibits polyol pathway activity in diabetic and galactosemic rats
56. The influence of aldose reductase inhibition and nerve myo-inositol on axonal transport and nerve conduction velocity in rats with experimental diabetes
57. Sorbitol, inositol and nerve conduction in diabetes
58. Prevention of defects of axonal transport and nerve conduction velocity by oral administration of myo-inositol for an aldose reductase inhibitor in streptozotocin diabetic rat
59. Myo-inositol and sorbitol metabolism in relation to peripheral nerve function in experimental diabetes in the rat: The effect of aldose reductase inhibition
60. Effect of new aldose reductase inhibitor, (E)-3-carboxymethyl-5-[(2E)-methyl-3-phenylpropenyli-dene]rhodanine (ONO-2235) on peripheral nerve disorders in streptozotocin diabetic rats
61. Effect of aldose reductase inhibitor (ONO-2235) on somatic and autonomic nervous dysfunction in streptozotocin-induced diabetic rats
62. Prevention of axonal transport defects, in vagus and sciatic nerves of diabetic rats, by aldose reductase inhibition
63. Prevention and reversal of defective axonal transport and motor nerve conduction velocity in rats with experimental diabetes by treatment with the aldose reductase inhibitor sorbinil
64. Red blood sorbitol as an indicator of polyol pathway activity. Inhibition by sorbinil in insulin-dependent diabetic subjects
65. Prevention of peripheral nerve dysfunction by an aldose reductase inhibitor in streptozotocin diabetic rats
66. Slow orthograde axonal transport of radiolabelled protein in sciatic motoneurons of rats with short-term experimental diabetes: Effects of treatment with an aldose reductase inhibitor or myo-inositol
67. Effect of a fructose-rich diet and the aldose reductase inhibitor, ONO-2235, on the development of diabetic neuropathy in streptozotocin-treated rats
68. Properties of ICI 128, 436, a novel aldose reductase inhibitor, and its effects on diabetic complications in the rat
69. Polyol accumulation in galactosemic and diabetic rats: Control by an aldose reductase inhibitor
70. Prevention and reversal of galactose cataract in rats with topical sorbinil
71. The effect of a new aldose reductase inhibitor (tolrestat) in galactosemic and diabetic rats
72. Edema and increased endoneurial sodium in galactose neuropathy
73. Prevention by tolrestat of the biochemical and morphological changes in galactose-fed rats
74. Role of sorbitol pathway in neuropathy
75. The effect of aldose reductase inhibition on nerve conduction velocity in diabetic rats
76. Relation of glycemic control to diabetic complications and health outcomes
77. Pathophysiology and treatment of diabetic neuropathy
78. Neurophysiological changes in the central and peripheral nervous system of streptozotocin-diabetic rats. Course of development and effects of insulin treatment
79. Mechanisms of altered hemodynamic and metabolic responses to insulin in patients with insulin-dependent diabetes mellitus and autonomic dysfunction
80. The spatial distribution of fiber loss in diabetic polyneuropathy suggested ischaemia
81. Elevated plasma insulin-like growth factor binding protein-I levels in type 1 (insulin-dependent) diabetic patients with peripheral neuropathy
82. Insulin-like growth factor-I and IGF-I receptors in diabetic patients with neuropathy
83. Diabetic neuropathies: Features and mechanisms
84. Insulin and related neurotrophic factors in diabetic neuropathy
85. Implication of insulin-like growth factors in the pathogenesis genesis of diabetic neuropathy
86. Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with type 1 diabetes mellitus
87. Nerve blood flow in early experimental diabetes in rats: Relation to conduction deficits
88. Endoneurial blood flow and oxygen tension in the sciatic nerves of rats with experimental diabetic neuropathies
89. Diabetes impairs sciatic nerve hypremia induced by surgical trauma: Implications for diabetic neuropathy
90. Effects of very mild versus overt diabetes on vascular haemodynamics and barrier function in rats
91. A prospective quantitative study of sensory deficits following whole sural nerve biopsies in diabetic and nondiabetic patients: Surgical approach and the role of collateral sprouting
92. Glucose-induced microvascular functional changes in nondiabetic rats are stereo-specific and are not prevented by an aldose reductase inhibitor
93. Hyperemia of injured peripheral nerve: Sensitivity to CGRP antagonism
94. The influence of indomethacin and guanethidine on experimental streptozotocin diabetic neuropathies
95. Normal blood flow but lower oxygen tension in diabetes of young rats: Microenvironment and the influence of sympathectomy
96. Dorsal root ganglia microenvironment of female BB/Wistar diabetic rats with mild neuropathy
97. + ATPase activity, and vascular supply in STZ-D rats
98. ++ antagonists, nimodipine, on existing diabetic neuropathy in the BB/Wor rat
99. ++ antagonists, nimodipine, of an existing diabetic neuropathy in the streptozotocin-induced diabetic rats
100. Effects of endothelin receptor antagonism with bosentan on peripheral nerve function in experimental diabetes
101. Vascular factors in diabetic neuropathy
102. Diabetes mellitus prevents capsaicin from inducing hyperaemia in the rat sciatic nerve
103. The influence of sulindac on experimental streptozotocin-induced diabetic neuropathy